MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)—implementation of a national guideline in Canada

Table 3 Overall odds ratios for use of MgSO4 for fetal NP as derived from segmented regression analysis

	Optimal use*	p value	Underuse*	p value	Suboptimal use*	p value
Odds ratio for use in pre-MAG-CP, per month†	1.004 [0.997, 1.01]	0.226	0.995 [0.99, 1.00]	0.104	1.18 [1.08, 1.28]	< 0.001
Immediate change in odds just after intervention†	1.84 [1.51, 2.24]	< 0.001	0.47 [0.34, 0.65]	< 0.001	2.18 [1.04, 4.58]	0.038
Change in odds ratio after intervention compared to pre-MAG-CP, per month†	1.02 [1.00, 1.04]	0.044	0.97 [0.95, 0.99]	0.002	0.86 [0.79, 0.94]	< 0.001
Odds ratio for use in MAG-CP era, per month†	1.02 [1.01, 1.03]	< 0.001	0.97 [0.95, 0.98]	< 0.001	1.01 [1.001, 1.02]	0.027

*Optimal use refers to both women who received MgSO4 for fetal NP when indicated, as well as women who did not receive MgSO4 for fetal NP when it was not indicated. Underuse refers to eligible women who should have received MgSO4 for fetal NP but did not. Suboptimal use refers to women who received MgSO4 too early (not within 24 h before birth) or at ≥ 32 weeks. †Segmented regression analysis was adjusted for antenatal administration of corticosteroids

ISSN: 1748-5908